Last reviewed · How we verify

AP-472 — Competitive Intelligence Brief

AP-472 (AP-472) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor antagonist. Area: Psychiatry.

phase 2 Serotonin receptor antagonist 5-HT2A Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

AP-472 (AP-472) — Appello Pharmaceuticals, Inc.. AP-472 is a small molecule that targets the serotonin receptor 5-HT2A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AP-472 TARGET AP-472 Appello Pharmaceuticals, Inc. phase 2 Serotonin receptor antagonist 5-HT2A
Clozaril CLOZAPINE Jazz Pharmaceuticals marketed Atypical Antipsychotic [EPC] D2, 5-HT2A 1989-01-01
Quetiapine and Topiramate Quetiapine and Topiramate University of Cincinnati marketed Atypical antipsychotic + anticonvulsant mood stabilizer combination D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Mescaline sodium enteric-coated tablets Mescaline sodium enteric-coated tablets Xiangya Hospital of Central South University marketed Serotonin receptor agonist; psychedelic 5-HT2A receptor (primary); non-selective serotonin receptors
Trazodone + PAP therapy Trazodone + PAP therapy VA Office of Research and Development marketed Serotonin antagonist and reuptake inhibitor (SARI) + mechanical ventilation device Serotonin transporter (SERT); serotonin 5-HT2A receptor antagonism
Perospirone hydrochloride tablets Perospirone hydrochloride tablets Shanghai Mental Health Center marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor
Aripiprazole tablet Aripiprazole tablet All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Serotonin receptor antagonist class)

  1. Addpharma Inc. · 2 drugs in this class
  2. Shire · 2 drugs in this class
  3. Gedeon Richter Plc. · 1 drug in this class
  4. Geropharm · 1 drug in this class
  5. H. Lundbeck A/S · 1 drug in this class
  6. Infan Industria Quimica Farmaceutica Nacional · 1 drug in this class
  7. Phytopharm Consulting Brazil · 1 drug in this class
  8. Taisho Pharmaceutical Co., Ltd. · 1 drug in this class
  9. Aclaris Therapeutics, Inc. · 1 drug in this class
  10. Visirna Therapeutics HK Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AP-472 — Competitive Intelligence Brief. https://druglandscape.com/ci/ap-472. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: